牛牛AI助手已提取核心信息
Biomerica, Inc. reported its financial performance for the quarter ended November 30, 2023, with net sales increasing by 6% to $1,567,000 compared to $1,482,000 in the same period last year. The rise in sales was primarily driven by higher demand for food intolerance products and increased contract manufacturing billings. Cost of sales was $1,242,000, or 79% of net sales, up from 76% in the previous year. The company experienced a net loss of $1,507,000, a slight improvement from a net loss of $1,626,000 in the prior year. Basic and diluted net loss per common share was $(0.09), compared to $(0.12) in the previous year. The company's cash and cash equivalents stood at $7,134,000, with a working capital of $8,443,000. Biomerica's business development included the FDA clearance of its new HP Detect Stool...Show More
Biomerica, Inc. reported its financial performance for the quarter ended November 30, 2023, with net sales increasing by 6% to $1,567,000 compared to $1,482,000 in the same period last year. The rise in sales was primarily driven by higher demand for food intolerance products and increased contract manufacturing billings. Cost of sales was $1,242,000, or 79% of net sales, up from 76% in the previous year. The company experienced a net loss of $1,507,000, a slight improvement from a net loss of $1,626,000 in the prior year. Basic and diluted net loss per common share was $(0.09), compared to $(0.12) in the previous year. The company's cash and cash equivalents stood at $7,134,000, with a working capital of $8,443,000. Biomerica's business development included the FDA clearance of its new HP Detect Stool Antigen ELISA test and the launch of its inFoods IBS product with certain gastroenterology groups. The company is also focusing on expanding its inFoods IBS product and developing new diagnostic products. For future plans, Biomerica is working on increasing sales, reducing expenses, and may seek additional financing through debt and equity financing to meet operating cash requirements and strategic growth objectives beyond the next year.
Biomerica, Inc.公布了截至2023年11月30日的季度财务业绩，净销售额从去年同期的148.2万美元增长了6％，达到15.67万美元。销售额的增长主要是由对食物不耐受产品的需求增加和合同制造账单的增加所推动的。销售成本为124.2万美元，占净销售额的79％，高于去年的76％。该公司的净亏损为1,507,000美元，较上一年的净亏损1,626,000美元略有改善。普通股每股基本亏损和摊薄后的净亏损为0.09美元（0.09美元），而去年为0.12美元。该公司的现金及现金等价物为7,134,000美元，营运资金为8,443,000美元。Biomerica的业务发展包括美国食品药品管理局...展开全部
Biomerica, Inc.公布了截至2023年11月30日的季度财务业绩，净销售额从去年同期的148.2万美元增长了6％，达到15.67万美元。销售额的增长主要是由对食物不耐受产品的需求增加和合同制造账单的增加所推动的。销售成本为124.2万美元，占净销售额的79％，高于去年的76％。该公司的净亏损为1,507,000美元，较上一年的净亏损1,626,000美元略有改善。普通股每股基本亏损和摊薄后的净亏损为0.09美元（0.09美元），而去年为0.12美元。该公司的现金及现金等价物为7,134,000美元，营运资金为8,443,000美元。Biomerica的业务发展包括美国食品药品管理局批准其新的HP Detect Stool 抗原ELISA试验，以及向某些胃肠病学团体推出InFoods肠易激综合征产品。该公司还专注于扩展其InFoods IBS产品和开发新的诊断产品。对于未来的计划，Biomerica正在努力增加销售额，减少开支，并可能通过债务和股权融资寻求额外融资，以满足明年以后的运营现金需求和战略增长目标。
有用
没用
